Skip to main content

Table 2 Multivariate analysis of survival by lymph node ratio and pN stage

From: Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy

Characteristic

LRFS

OS

 

HR (95% CI)

p

HR (95% CI)

p

Age (y)

    

 ≤ 35 vs. > 35

1.664 (1.082-2.558)

0.020*

 

Menopausal status

    

 Pre- vs. postmenopausal

1.623 (1.106-2.383)

0.105

 

Tumor size

    

 T3-4 vs. T1-2

1.636 (1.029-2.600)

0.037

1.392 (0.917-2.113)

0.121

ER status

    

 Negative vs. positive

1.536 (1.095-2.155)

0.013*

1.054 (0.699-1.590)

0.802

PR status

    

 Negative vs. positive

1.626 (1.148-2.302)

0.317

1.490 (1.040-2.136)

0.030*

HER-2-neu status

    

 Positive vs. negative

 

1.208 (0.888-1.644)

0.228

Hormone therapy

    

 None vs. yes

1.180 (0.731-1.904)

0.498

1.570(1.093-2.255)

0.015*

Lymph node ratio

    

 < 0.20

1 (Reference)

 

1 (Reference)

 

 0.21-0.65

1.886 (1.273-2.794)

0.002*

1.964 (1.387-2.782)

<0.001*

 > 0.65

5.013 (3.191-7.877)

<0.001*

7.381 (5.161-10.557)

<0.001*

Number of positive lymph nodes

    

 pN1

1 (Reference)

   

 pN2

0.828 (0.476-1.442)

0.522

1.327 (0.808-2.179)

0.263

 pN3

0.894 (0.437-1.828)

0.907

1.654 (0.904-3.027)

0.103

  1. LRFS, Locoregional recurrence-free survival; OS, Overall survival; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, Human epithelial growth factor receptor family 2; HR, Hazard ratio; CI, Confidence interval.
  2. *p<0.05 indicates a significant difference.